Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology
+$0.10 today
- Market cap
- $1.30B
- Beta
- 1.18
- P/E (TTM)
- -17.7
- EPS (TTM)
- -$0.35
Volume 3.38M
Average 2.73M
TSHA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Taysha Gene Therapies, Inc.NASDAQ: TSHA
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 45.6% from a year ago
Cash & equivalents stood at $455.41M at the end of Q2 FY2026, up 45.6% from a year earlier and up 64.7% from the prior quarter. Over 3 fiscal years it compounded at +53.8% a year.
Context
- Cash & equivalents amounted to 96.8% of total assets at the end of Q2 FY2026, up 3.0 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +45.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 319.77M USD
- Year-over-year change
- +130.0%
- 4-year CAGR
- +21.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 319.77M | +130.0% |
| FY2024 | 2024-12-31 | 139.04M | -3.4% |
| FY2023 | 2023-12-31 | 143.94M | +63.8% |
| FY2022 | 2022-12-31 | 87.88M | -41.1% |
| FY2021 | 2021-12-31 | 149.1M | — |
Cash & Equivalents vs competitors
How TSHA compares with its peers on the latest reported figures
- TSHA's Jun 2026 cash & equivalents of $455.41M is the 2nd highest of the 9 companies compared; the peer median is $66.93M.
- Its year-over-year change of +45.6% is the 5th highest of 9, against a peer median of +37.5%.
- Cash & equivalents amounts to 96.8% of total assets for TSHA, versus a peer median of 18.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $464.45M | +92.8% | -6.1% | 14.6% | |
| Jun 2026 | $455.41M | +45.6% | +53.8% | 96.8% | |
| Mar 2026 | $184.76M | +78.4% | +188.7% | 98.8% | |
| Mar 2026 | $124.16M | +75.4% | +8.2% | 47.2% | |
| Mar 2026 | $72.49M | -45.7% | +4.8% | 14.1% | |
| Mar 2026 | $61.37M | +285.1% | +76.7% | 30.9% | |
| Mar 2026 | $49.61M | -0.4% | -18.0% | 17.4% | |
| Mar 2026 | $43.31M | -42.1% | -12.9% | 19.7% | |
| Mar 2026 | $15.23M | -88.3% | -29.2% | 4.5% | |
| Peer median (excluding TSHA) | $66.93M | +37.5% | -0.6% | 18.6% | |
Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 149.1M | 87.88M | 143.94M | 139.04M | 319.77M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 6.63M | 1.19M | 3.42M | 892K | 1.45M |
| Total Current Assets | 159.6M | 96.42M | 149.87M | 142.13M | 324.65M |
| Property, Plant & Equipment (Net) | 50.61M | 25.91M | 20.41M | 15.87M | 16.18M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 2.64M | 0 | 0 | 0 | 2.32M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.11M | 3.95M | 2.46M | 2.37M | 183K |
| Total Non-current Assets | 54.35M | 29.86M | 22.86M | 18.23M | 18.67M |
| Total Assets | 213.96M | 126.28M | 172.73M | 160.36M | 343.32M |
| Account Payables | 21.76M | 10.95M | 6.37M | 3.59M | 6.28M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 33.56M | 18.11M | 9.77M | 0 |
| Other Current Liabilities | 4.14M | 4.63M | 4.99M | 6.43M | 10.85M |
| Total Current Liabilities | 51.75M | 62.79M | 36.76M | 26.23M | 26.55M |
| Long-term Debt | 37.19M | 37.97M | 40.51M | 43.94M | 18.17M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 3.74M | 4.13M | 1.58M | 1.31M | 51.66M |
| Total Non-current Liabilities | 66.83M | 62.54M | 61.04M | 62.61M | 69.83M |
| Total Liabilities | 118.57M | 125.33M | 97.79M | 88.84M | 96.38M |
| Common Stock | 0 | 1K | 2K | 2K | 3K |
| Retained Earnings | (235.65M) | (401.44M) | (513.01M) | (602.31M) | (711.3M) |
| Accumulated OCI | 0 | 0 | 0 | (4.03M) | (192K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 95.38M | 949K | 74.94M | 71.53M | 246.94M |
| Total Debt | 63.09M | 59.93M | 61.11M | 63.18M | 18.17M |
| Net Debt | (86.01M) | (27.95M) | (82.83M) | (75.86M) | (301.6M) |
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
Intrinsic Alpha fair value
Locked
Current Price
$3.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.